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The mitotoxin bFGF-SAP combines the targeting specificity of basic fibrob-
last growth factor (bFGF) with the cytotoxicity of the ribosome inactivating
protein saporin (SAP) to exert a cytotoxic effect on proliferating smooth mus-
cle cells after arterial injury. Sprague-Dawley rats undervvent carotid artery
balloon injury and received an intravenous bolus of vehicle (n = 12). 5 (n =
10), 15 In = 11), or 20 (n = 10) JLg/kg bFGF-SAP at 0, 3, 6, and 9 days after
injury. Rats were euthanized at 14 days, and carotid arteries were analyzed
by computerized morphometry.
Results:
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The threshold pulse dose for reduced neointimal proliferation by bFGF-
SAP was 15 /Lgfkg with no further reduction in proliferation with 20 JL9/kg.
Reduced neointimal proliferation did not reach statistical significance with
the 5 /Lgfkg dose. When given as a continuous intravenous infusion (n =
8 ratsl at 15 /Lg/kg/day for 14-days after arterial injury (cumulative dose of
210 JLg/kgl, bFGF-SAP did not inhibit neointima formation. Arterial medial
thickness and area within the internal elastic lamina were similar in all groups.
Conclusion: Pulse dosing, but not a continuous infusion, of bFGF-SAP re-
sulted in a 46% reduction in neointimal proliferation after arterial injury. The
effect of bFGF-SAP appears to be selective for the neointima as there was
no associated medial thinning or arterial wall dilatation. Further studies op-
timizing the administration of bFGF-SAP and evaluation of its mechanism of
action will be important in utilizing this mitotoxin in the prevention of resteno-
sis.
Conclusion: Periadventitially applied polymeric fl-cyclodextrin sulfate pro-
duces sustained inhibition of intimal thickening following vascular injury, pos-




14 Day B8 Day
Smooth muscle cell proliferation is critical to the pathogenesis of restenosis.
Oxygen-derived radicals are known cell mitogens. We tested whether ebse-
len, a selenium-containing heterocyclic compound with antioxidant activity
could reduce intimal thickening and increase luminal size after balloon injury
(81) in the coronary artery model. Nineteen normolipemic pigs were given
(811 of the LAD and LCX coronary arteries. At random 9 pigs were pretreated
with ebselen (2.4 g twice per day) for 3 days before 81 and continued un-
til sacrifice (2 weeks after BI). Coronary atrery sections were evaluated by
computer morphometry. The maximal intimal thickness (MIT), intimal area
(IA) luminal perimeter (LP). vessel perimeter (VP), and fracture length (FL)
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Improves the Response to Balloon Injury in the
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Low Molecular Weight Heparin and Hirudin
Reduce Neointimal Proliferation After Coronary
Angioplasty
Sustained Inhibition of Intimal Thickening:
Beneficial In Vitro and In Vivo Effects of
Polymeric p·Cyclodextrin Sulfate
PEG-H 3 days PEG-H 14days CLl14 days CON
1 mg/kg bolus 1 mg/kg bolus 150 Uikg bolus 100 U/kg
5 mg/kg 1xlday 5 mglkg 75 Ulkg heparin-
In ~ 11) 1xlday 2x/day bolus
In ~ 9) In ~ 8) In ~ 7)
Injury score 1.7 ± 0.4 2.2 ± 0.4 2.1±0.4 1.8 ± 0.3
Mean neointimal
thickness (mm) 0.33 ± 015 # 037±016# 039 ± 015 # 0.68 ± 0.18
Vessel wall area
(% vessel area) 47.0 ± 7.6 # 54.4 ± 9.4 # 51.5±21.4# 74 ± 113
#p < 0.02 vs CON
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In conclusion, a 2-hour infusion of hirulog at the time of angioplasty re-
duced angiographic restenosis as well as cross-sectional area narrowing by
plaque in this atherosclerotic rabbit model.
Conclusion: 80th CLI and PEG-H reduce neointimal proliferation after coro-
nary angioplasty, compared to standard clinical anticoagulation with a hep-
arin bolus.
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Proliferation of medial smooth muscle cells (SMC) plays a major role in
restenosis after coronary angioplasty and can be inhibited by heparin.
Platelets stimulate SMC proliferation and their aggregation post angioplasty
can be reduced by the direct thrombin inhibitor hirudin. In a porcine coro-
nary stent angioplasty model we studied the effect of 3 and 14 days treat-
ment with a novel polyethylenglycol - conjugated hirudin (PEG-H) versus
chronic low molecular weight heparin c1ivarine (CLI) versus acute unfraction-
ated heparin as a control (CON). 4 weeks post a gioplasty, hearts were periu-
sion fixed and 6 slices per angioplasty segment were analysed for neointimal
thickness and vessel wall area (% of total vessel crossectional area). Vessel
injury in each slice was assessed using a semiquantitative score (0: lamina
elastica interna intact, to 3: penetration through media). PEG-H prolonged
partial thromboplastin time to 2-2.5 x control throughout treatment period.
Results:
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Intimal thickening after vascular injury is thought to be modulated in part by
heparin binding growth factors. We hypothesized that placement of a thera-
peutic polymer in the periadventitial space capable of tightly binding growth
factors might alter the vascular response to injury. We first tested the effects
of polymeric fl-cyclodextrin sulfate (P-CDS) on smooth muscle cell (SMC)
proliferation using a quantitative protein accumulation assay. Incubation of
rat aortic SMC (2500 cells/microwell in 10% FCS, n = 96) with P-CDS was
associated with a dose dependent inhibition of proliferation. with maximum
inhibition "'50% vs. control at 1 mg/ml (p < 0.05). The proliferation assays
were repeated using media containing only recombinant basic FGF (bFGF,
5 ng/ml) which had been exposed to P-CDS (1 mg/ml) for varying periods
of time (1 min to 3 days). We demonstrated a time dependent reduction of
the bFGF mitogenic activity, with complete removal of all activity within 60
minutes. Using radiolabeled bFGF (0.25 JLg/ml), we observed rapid associ-
ation (0.23 min-1) and dissociation (7.3 x 10-5 min-1) rates, suggesting a
high affinity interaction. We then tested the effects of P-CDS on SMC mi-
gration (using a linear under-agarose assay) and demonstrated treatment of
rat aortic SMC with P-CDS (1 mg/ml) in the agar resulted in "'50% reduction
in SMC migration vs. control at 72 hours (p < 0.05). Finally, the effects of
P-CDS in vivo were studied in the rat carotid balloon injury model. SD rats
("'350 g) were randomized to periadventitial P-CDS (10 mg) or no treatment,
additional rats received treatment with unsulfated fl-cyclodextrin polymer(P-
CD). Morphometric analyses at 4 (n = 20), 14 (n = 59), and 88 days (n = 14)
demonstrated >40% reduction of intimal area and intima/media area ratios
only in the P-CDS rats. No inhibition was seen with P-CD treated rats. De-
creased bromodeoxyuridine labeled SMC (79 ± 11 vs 144 ± 23, p = 0.Q1)
were noted in the intima of P-CDS rats at 14 days. At all time points, there
were reduced total SMC counts and no reduction in % proliferation in the
intima of P-CDS rats, suggesting greater effects on SMC migration than pro-
liferation in vivo. Endothelial cell regrowth (by Evans blue staining) was in-
creased in the P-CDS rats at 14 (4.4 vs 2.2 mm, p = 0.09) and 88 days (13.0
vs 9.2 mm, p < 0.01).
